Unknown

Dataset Information

0

Clinical and Cardiac Safety of Long-term Levofloxacin in Children Treated for Multidrug-resistant Tuberculosis.

ABSTRACT: Safety concerns persist for long-term pediatric fluoroquinolone use. Seventy children (median age, 2.1 years) treated with levofloxacin 10-20 mg/kg once daily for multidrug-resistant tuberculosis (median observation time, 11.8 months) had few musculoskeletal events, no levofloxacin-attributed serious adverse events, and no Fridericia-corrected QT interval >450 ms. Long-term levofloxacin was safe and well tolerated.

SUBMITTER: Garcia-Prats AJ 

PROVIDER: S-EPMC6233673 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Clinical and Cardiac Safety of Long-term Levofloxacin in Children Treated for Multidrug-resistant Tuberculosis.

Garcia-Prats Anthony J AJ   Draper Heather R HR   Finlayson Heather H   Winckler Jana J   Burger André A   Fourie Barend B   Thee Stephanie S   Hesseling Anneke C AC   Schaaf H Simon HS  

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20181101 11

Safety concerns persist for long-term pediatric fluoroquinolone use. Seventy children (median age, 2.1 years) treated with levofloxacin 10-20 mg/kg once daily for multidrug-resistant tuberculosis (median observation time, 11.8 months) had few musculoskeletal events, no levofloxacin-attributed serious adverse events, and no Fridericia-corrected QT interval >450 ms. Long-term levofloxacin was safe and well tolerated. ...[more]

Similar Datasets

Unknown Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis.
| S-EPMC5786780 | biostudies-literature
Unknown Pharmacokinetics, Safety, and Dosing of Novel Pediatric Levofloxacin Dispersible Tablets in Children with Multidrug-Resistant Tuberculosis Exposure.
| S-EPMC6437514 | biostudies-literature
Unknown Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis Patients.
| S-EPMC5527618 | biostudies-literature
Unknown Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis.
| S-EPMC4366580 | biostudies-literature
Unknown Pharmacokinetics and Dosing of Levofloxacin in Children Treated for Active or Latent Multidrug-resistant Tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands.
| S-EPMC5117358 | biostudies-literature
Unknown Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis.
| S-EPMC6260169 | biostudies-literature
Unknown Current therapies for the treatment of multidrug-resistant tuberculosis in children in India.
| S-EPMC5942143 | biostudies-other
Unknown Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: Combined data from two prospective observational studies.
| S-EPMC6490911 | biostudies-literature
Unknown Determination of plasma concentrations of levofloxacin by high performance liquid chromatography for use at a multidrug-resistant tuberculosis hospital in Tanzania.
| S-EPMC5283651 | biostudies-literature
Unknown Evaluation of Saliva as a Potential Alternative Sampling Matrix for Therapeutic Drug Monitoring of Levofloxacin in Patients with Multidrug-Resistant Tuberculosis.
| S-EPMC6496077 | biostudies-literature